Inspire Announces Presentations at Two European Scientific,Conferences ( DURHAM N.C.--(BUSINESS WIRE)--Jun 12 ...)

Inspire Announces Presentations at Two European Scientific,Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI) being held June 9-13, 2007 in Goteborg, Sweden and at the 30th European Cystic Fibrosis Society (ECFS) Conference being held June 13-16, 2007 in Belek, Turkey.

The EAACI Congress includes two presentations with clinical data on bilastine, a compound in development by FAES Farma, S.A. for the treatment of allergic rhinitis, which is partnered with Inspire in the United States and Canada, and one presentation with scientific data on epinastine, bilastine and other antihistamines for treating allergies. -0-

-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily

   Bilastine with Cetirizine and Placebo for the Treatment of Seasonal

   Allergic Rhinitis

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Treatment with Bilastine Improves Symptoms in Patients with

   Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy

   and Safety of Once Daily Bilastine with Desloratadine and Placebo

   for the Treatment of Seasonal Allergic Rhinitis)

   Poster and brief oral presentation on Tuesday, June 12, 2007


-- Evaluation of Muscarinic Receptor Antagonism by Antihistamines

   Poster and brief oral presentation on Tuesday, June 12, 2007

The ECFS Conference includes two presentations with clinical data on denufosol, a compound in development by Inspire for the treatment of cystic fibrosis. -0-

-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists -

   Evidence of High Lung Delivery and Minimal Systemic Exposure

   Poster presentation on Thursday and Friday, June 14-15, 2007 and

   oral presentation on Thursday, June 14, 2007


-- Reactive Airway Disease and
'"/>




Page: 1 2 3 
Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine
Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in
Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on
GlycoPEGylated Factor VIIa at the XXI Congress of the International
Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease

Post Your Comments:

(Date:3/12/2010)... Pharmaceuticals (Nasdaq: ENDP ) announced today the appointment of Julie McHugh as the company,s chief operating officer, effective March 15, 2010 ... ... ... ... ...

(Date:3/12/2010)... ANX ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the proposed proprietary name "Exelbine™" for the Company,s product candidate ANX-530 ... ... ... ... ...

(Date:3/11/2010)... With obesity in America reaching alarming levels -- across our adult and youth populations -- ... wearable body-monitoring technology either in conjunction with a group weight loss program or as part ... more weight than individuals who attempted to battle the bulge solo. ... ... , ...

Breaking Medicine Technology:Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer 2 Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer 3 Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer 4 Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer 5 Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer 6 ADVENTRX Receives Brand Name Acceptance for ANX-530 2 ADVENTRX Receives Brand Name Acceptance for ANX-530 3 ADVENTRX Receives Brand Name Acceptance for ANX-530 4 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 2 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 3 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 4 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 5 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 6 China Biotics Inc Announces Conference Call to Discuss First Quarter Fiscal 2010 Financial Results 54556 1 China Biotics Inc Announces Conference Call to Discuss First Quarter Fiscal 2010 Financial Results 54556 2 Americans United for Life Applauds Decision Protecting Women From Dangers of RU 486 54554 1 Americans United for Life Applauds Decision Protecting Women From Dangers of RU 486 54554 2 PerfectServe Launches New Web Site 54552 1 PerfectServe Launches New Web Site 54552 2

[0] Endo Pharmaceuticals Announces Appointment of New Chief Operating Officer [0] ADVENTRX Receives Brand Name Acceptance for ANX-530 [0] The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight

... Sept. 4 /Xinhua-PRNewswire-FirstCall/ --,Pharmaceutical company Pharmaxis (ASX: PXS; ... first subject into its second pivotal Phase 3,clinical ... The Phase 3 trial is being conducted in ... is the final clinical step before,Pharmaxis seeks approval ...

... is National Vascular Disease Awareness Month, ... a clinical-stage drug-development company commercializing new drugs,for ... today that it has begun,to enroll patients ... its lead drug,candidate trans sodium crocetinate (TSC). ...

Other Medicine Technology:Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2 Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3 Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2 Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3 Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4

Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

(Date:3/15/2010)... manufacturer United Feather & Down and world-renowned sleep expert Dr. James ... , ... (PRWEB) March 15, 2010 -- When top ... on sleep, they look to “Power Sleep” author and Cornell University ... sleep products for their customers, they turn to United Feather & ...

(Date:3/15/2010)... + Lomb has named Fred Hassan as chairman of the Board of Directors and has named Brent Saunders as chief executive officer ... ... , ... ... ...

(Date:3/15/2010)... of improvement , ... , , ... ... ... TORONTO , March 15 /PRNewswire-FirstCall/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the ...

(Date:3/15/2010)... 15 Genoptix, Inc. ( GXDX), a specialized laboratory services provider, today announced the Company,s participation at the Barclays Capital 2010 Global Healthcare Conference at ... ... , ... ... ...

(Date:3/15/2010)... , ... ... - Abu Dhabi Hosts Inaugural Congress 12 - 14 March 2010 , ... , ... ...

[0] Two Top Sleep Experts Team Up On New Pillow Collection [0] Bausch + Lomb Names Fred Hassan as Chairman, Brent Saunders as Chief Executive Officer [0] Patheon reports first quarter fiscal 2010 results [0] Genoptix Announces Participation at the Barclays Capital 2010 Global Healthcare Conference [1] Over 500 Doctors Descend Into Abu Dhabi to Attend the 1st International Abu Dhabi Diabetes Congress

... to restore their cognitive function better as they age. ... protect against dementia// is conflicting - some studies do ... report, from researchers, is therefore of especial interest. ... different countries for a few years - assessing them ...

... probably get more benefit from investing in gymnasium membership and ... researchers at the Cleavland University // it is better to ... a machine Exercise machines are often advertised in a misleading ... fit to your body, and you may need to learn ...

... and late menopause have better chances of surviving a broken ... bone disease.// Most women who sustain a hip fracture survive, ... ,Researchers in Norway sought to investigate the impact a woman's ... when she first has a child and age at which ...

... team of scientists, based in UK, have grown human ... attempt to control the development of embryonic stem cells. ... of replacement tissues for treating neurodegenerative conditions like Parkinson's ... heavy competition over the past few years to capture ...

... that if women drink too much coffee during pregnancy can ... fits.//Studies have found that caffeine may be linked to the ... have been briefly starved of oxygen. ,A research team ... cells from the hippocampus, a part of the brain that ...

... salad goods may help reduce the risk of osteoporosis - ... usually after the menopause. Reported researchers at the University ... ,They said that 1g of onion a day can ... where calcium seeps from the bones making them brittle. And ...

Other Medicine News:Health News:Stem cell research 2

Hormone replacement therapy helps women Invest on gym memberships Early puberty more resistance,Stem cell research Caffeine can induce epilepsy in newborns Miraculous Salads

... stage hermetically sealed refrigeration system ... cabinet interior achieving -35C*. This ... TS-2000 alarm monitoring system and ... to comply with Australian Standard ...

Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....

... Designed for ease of use and ... has smooth edges for comfort and is ... one-size-fits-all to a perfect fit. For hard ... a trach collar to your specifications. Don't ...

Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....

Medicine Products:

Upright Plasma Freezer Adult Portex Velcro® Tracheostomy Tube Holder Adult One Size Fits All Tracheostomy Collar™Pediatric Portex Velcro® Tracheostomy Tube Holder

( DURHAM N.C.--(BUSINESS WIRE)--Jun 12 ...)Inspire Announces Presentations at Two European Scientific,Conferences,Health